REG - Yourgene Health PLC - Strategic partnership extended with Ambry Genetics

Yourgene HealthAnnouncement

25/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1285Ja&default-theme=true

RNS Number : 1285J  Yourgene Health PLC  25 April 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Strategic partnership extended with Ambry Genetics

Expanding market access of technology

 

Manchester, UK - 25 April 2022: Yourgene (AIM: YGEN), a leading international
molecular diagnostics group, announces the Company has extended its strategic
partnership with Ambry Genetics ('Ambry'), a leading US precision medicine
company, with a new Genomic Services collaboration. The new agreement will
allow both companies access to each other's technology and assays, expanding
market access and penetration for both.

 

On 9 June 2021 Yourgene announced a multi-year licence and supply agreement
with an unnamed US partner (the 'Partner') for access to the Company's
Noninvasive prenatal testing (NIPT) technology which came into effect on 1
April 2022. Yourgene can now confirm that the Partner is Ambry Genetics, a
part of REALM IDx, Inc.

 

The agreement will enable the development of NIPT-related solutions as a part
of Ambry's Women's Health portfolio expansion. Along with carrier screening,
the portfolio will include Ambry's CARE (Comprehensive Assessment Risk and
Education) Program, a digital tool that provides a streamlined, end-to-end
solution for physicians to provide risk screening and education on genetic
testing, as well as facilitate test ordering, result reporting and access to
genetic counselors.

 

Currently, Ambry's CARE Program is being used to help identify patients at
higher risk of developing cancer, but it will be expanded to include NIPT and
Carrier Screening to provide physicians one easy-to-use platform with a
comprehensive set of genetic testing, education and support options for their
patients.

 

"To truly add value for physicians, you need to have a robust screening
technology along with a delivery program that helps to educate and ensure that
patients understand the testing that they are being offered" said Tom
Schoenherr, Chief Executive Officer of Ambry Genetics. "We believe the
partnership with Yourgene and our CARE Program will help to standardize
informed care and remove disparities in its delivery."

 

Yourgene expects that this partnership will underpin its future growth and
create a greater number of commercial opportunities for both companies.

 

Lyn Rees, Chief Executive Officer, commented: "This is a multi-level
partnership with a leader in the field of precision medicine. Ambry will
provide an addressable US market for NIPT and a range of class leading
oncology products and services to bring to our recently expanded UK based
genomic services footprint. We very much look forward to strengthening and
broadening our relationship with Ambry, cementing our relationship with this
prestigious US company."

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 

 Yourgene Health plc                                Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                  investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)               Tel: +44 (0)20 7213 0880
 Liam Murray / James Caithie / Ludovico Lazzaretti

 Singer Capital Markets (Joint Corporate Broker)    Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                                 Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 Paul McManus / Lianne Applegarth / Alice Woodings  Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

 

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling genomic medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

About Ambry Genetics

Ambry Genetics, a part of REALM IDx, Inc., translates scientific research into
clinically actionable test results based upon a deep understanding of the
human genome and the biology behind genetic disease. It is a leader in genetic
testing that aims to improve health by understanding the relationship between
genetics and disease. Its unparalleled track record of discoveries over 20
years, and growing database that continues to expand in collaboration with
academic, corporate and pharmaceutical partners, means Ambry Genetics is first
to market with innovative products and comprehensive analysis that enable
clinicians to confidently inform patient health decisions.

 

Media Contacts

Brad Lotterman

REALM IDx Communications Director

blotterman@realmidx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAKLLADXAEFA